Prevalence of Dyslipidemia Among Antiretroviral-Naive HIV-Infected Individuals in China

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2015 Dec 4

PMID 26632908

Citations 17

Authors

Yinzhong Shen

Jiangrong Wang

Zhenyan Wang

Tangkai Qi

Wei Song

Yang Tang

Li Liu

Renfang Zhang

Hongzhou Lu

Affiliations

Soon will be listed here.

Abstract

Little is known about the epidemiological features of dyslipidemia among antiretroviral-naive HIV-infected individuals in China. We used a cross-sectional study design to estimate the prevalence of dyslipidemia in this population, and to identify risk factors associated with the presence of dyslipidemia. One thousand five hundred and eighteen antiretroviral-naive HIV-infected individuals and 347 HIV-negative subjects in China were enrolled during 2009 to 2010. Demographics and medical histories were recorded. After an overnight fast, serum samples were collected to measure lipid levels. Factors associated with the presence of dyslipidemia were analyzed by logistic regression. Mean total cholesterol (TC), low-density lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL) levels were lower in HIV-positive than HIV-negative subjects, but mean triglyceride (TG) was higher in HIV-positive subjects. The overall prevalence of dyslipidemia in HIV-positive and HIV-negative groups did not differ (75.6% vs. 73.7%, P = 0.580). However, the prevalence of high TC (8.4% vs. 28.2%, P < 0.001) and high LDL (8.5% vs. 62.6%, P < 0.001) was lower in HIV-positive than HIV-negative subjects, and the prevalence of high TG (33.9% vs. 17.0%, P < 0.001) and low HDL (59.6% vs. 11.2%, P < 0.001) was higher in HIV-positive than HIV-negative subjects. Logistic analysis showed that HIV positivity was significantly associated with both an increased risk of high TG and low HDL and a decreased risk of high TC and high LDL. The mean levels of TC, of LDL and of HDL showed an increasing trend with increasing CD4 count in HIV-positive subjects. Multivariable logistic regression found that lower CD4 count was significantly associated with both an increased risk of high TG and low HDL and a decreased risk of high TC in HIV-positive subjects. Among antiretroviral-naive HIV-infected Chinese adults, there was a high prevalence of dyslipidemia characterized by high TG and low HDL, which was associated with lower CD4 counts. These data support the assessment of lipid profiles before and after initiation of antiretroviral therapy regardless of age.

Citing Articles

Optimizing cardiometabolic risk in people living with human immunodeficiency virus: A deep dive into an important risk enhancer.

Kobe E, Thakkar A, Matai S, Akkaya E, Pagidipati N, McGarrah R Am J Prev Cardiol. 2024; 20:100888.

PMID: 39552706 PMC: 11566711. DOI: 10.1016/j.ajpc.2024.100888.

Prevalence of dyslipidemia and associated risk factors among Chinese people living with HIV.

Li L, Zhang Y, Yu A, Wang Z, Song J, Yu F Chin Med J (Engl). 2024; 137(23):2874-2876.

PMID: 39450891 PMC: 11649280. DOI: 10.1097/CM9.0000000000003336.

Effectiveness and safety of dolutegravir plus lamivudine in treating HIV in China, including outcomes of patients coinfected with tuberculosis.

Hou H, Ba H, Jin X, Luo P, Zhang Y, Li J Medicine (Baltimore). 2024; 103(27):e38558.

PMID: 38968505 PMC: 11224891. DOI: 10.1097/MD.0000000000038558.

Risk factors and longitudinal changes of dyslipidemia among Chinese people living with HIV receiving antiretroviral therapy.

Li X, Song X, Han Y, Qiu Z, Cao W, Li T BMC Infect Dis. 2023; 23(1):598.

PMID: 37705002 PMC: 10500758. DOI: 10.1186/s12879-023-08587-0.

Prevalence and Factors Associated with Dyslipidemia Among People Living with HIV/AIDS on Follow-Up Care at a Tertiary Care Hospital in Ethiopia: A Cross-Sectional Study.

Assefa A, Abiye A, Tadesse T, Woldu M Drug Healthc Patient Saf. 2023; 15:93-102.

PMID: 37546170 PMC: 10397381. DOI: 10.2147/DHPS.S395037.

References

. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

Tadewos A, Addis Z, Ambachew H, Banerjee S . Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group study. AIDS Res Ther. 2012; 9(1):31. PMC: 3499183. DOI: 10.1186/1742-6405-9-31. View

Erem C, Hacihasanoglu A, Deger O, Kocak M, Topbas M . Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study. Endocrine. 2008; 34(1-3):36-51. DOI: 10.1007/s12020-008-9100-z. View

Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M . Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011; 53(11):1130-9. DOI: 10.1093/cid/cir626. View

Kotler D . HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients. J Acquir Immune Defic Syndr. 2008; 49 Suppl 2:S79-85. DOI: 10.1097/QAI.0b013e318186519c. View

Zhang F, Dou Z, Ma Y, Zhang Y, Zhao Y, Zhao D . Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Infect Dis. 2011; 11(7):516-24. DOI: 10.1016/S1473-3099(11)70097-4. View

Visnegarwala F, Chen L, Raghavan S, Tedaldi E . Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection. J Infect. 2005; 50(4):331-7. DOI: 10.1016/j.jinf.2004.06.001. View

Armstrong C, Liu E, Okuma J, Spiegelman D, Guerino C, Njelekela M . Dyslipidemia in an HIV-positive antiretroviral treatment-naive population in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr. 2011; 57(2):141-5. PMC: 3125454. DOI: 10.1097/QAI.0b013e318219a3d1. View

Zhou H, Zheng Y, He Y, Chen Z, Liu M, Yin W . Evaluation of a 6-year highly active antiretroviral therapy in Chinese HIV-1-infected patients. Intervirology. 2010; 53(4):240-6. DOI: 10.1159/000302762. View

10.

Buchacz K, Weidle P, Moore D, Were W, Mermin J, Downing R . Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr. 2008; 47(3):304-11. DOI: 10.1097/qai.0b013e31815e7453. View

11.

Kanjanavanit S, Puthanakit T, Vibol U, Kosalaraksa P, Hansudewechakul R, Ngampiyasakul C . High prevalence of lipid abnormalities among antiretroviral-naive HIV-infected Asian children with mild-to-moderate immunosuppression. Antivir Ther. 2011; 16(8):1351-5. PMC: 3530027. DOI: 10.3851/IMP1897. View

12.

Asztalos B, Schaefer E, Horvath K, Cox C, Skinner S, Gerrior J . Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients. Atherosclerosis. 2005; 184(1):72-7. DOI: 10.1016/j.atherosclerosis.2005.04.013. View

13.

Anastos K, Lu D, Shi Q, Tien P, Kaplan R, Hessol N . Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr. 2007; 45(1):34-42. DOI: 10.1097/QAI.0b013e318042d5fe. View

14.

Rose H, Hoy J, Woolley I, Tchoua U, Bukrinsky M, Dart A . HIV infection and high density lipoprotein metabolism. Atherosclerosis. 2007; 199(1):79-86. PMC: 2518204. DOI: 10.1016/j.atherosclerosis.2007.10.018. View

15.

Monroe A, Fu W, Zikusoka M, Jacobson L, Witt M, Palella F . Low-Density Lipoprotein Cholesterol Levels and Statin Treatment by HIV Status Among Multicenter AIDS Cohort Study Men. AIDS Res Hum Retroviruses. 2015; 31(6):593-602. PMC: 4458749. DOI: 10.1089/AID.2014.0126. View

16.

Tsiodras S, Mantzoros C, Hammer S, Samore M . Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med. 2000; 160(13):2050-6. DOI: 10.1001/archinte.160.13.2050. View

17.

Rose H, Woolley I, Hoy J, Dart A, Bryant B, Mijch A . HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment. Metabolism. 2005; 55(1):90-5. DOI: 10.1016/j.metabol.2005.07.012. View

18.

Oh J, Hegele R . HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis. 2007; 7(12):787-96. DOI: 10.1016/S1473-3099(07)70287-6. View

19.

Shen Y, Wang Z, Liu L, Zhang R, Zheng Y, Lu H . Prevalence of hyperglycemia among adults with newly diagnosed HIV/AIDS in China. BMC Infect Dis. 2013; 13:79. PMC: 3574853. DOI: 10.1186/1471-2334-13-79. View

20.

Currier J, Lundgren J, Carr A, Klein D, Sabin C, Sax P . Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008; 118(2):e29-35. PMC: 5153327. DOI: 10.1161/CIRCULATIONAHA.107.189624. View